# YIRUI Pharmaceutical Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yirui-pharmaceutical-technology

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.yirui-pharma.com
- Latest round: Series A (Dec 19, 2023)
- Investors on record: 3

## About

Based in Hangzhou, China, YIRUI Pharmaceutical Technology specializes in developing innovative small molecule drugs, focusing on therapeutic solutions for complex autoimmune diseases and chronic inflammatory conditions.YIRUI Pharmaceutical Technology Co., Ltd. was founded in 2018 in Hangzhou, China. The company focuses on the research and development of targeted drugs. The founder, Xiaolu Wang, has a background in pharmaceuticals, although no prior companies are specified. YIRUI has successfully completed one funding round, with the most recent deal occurring on December 19, 2023.Hangzhou Yirui Pharmaceutical Technology Co., Ltd. specializes in the research and development of small molecule innovative targeted drugs, focusing primarily on therapeutic solutions for autoimmune diseases, diabetic complications, and chronic inflammatory conditions. Their main product, YR-001, is currently in Phase II clinical trials in the United States and is designed to address autoimmune skin diseases, which have significant unmet medical needs. The company adopts a strategic approach to drug development that emphasizes the integration of basic research with clinical application, ensuring timely transformations of research outcomes into market-ready products. Yirui Pharma's client base includes healthcare providers and pharmaceutical companies across both domestic and international markets, specifically targeting regions where there is a high prevalence of the conditions they aim to treat.Yirui Pharma has recently completed a Series A+ financing round, securing tens of millions of yuan to accelerate its research and clinical trial efforts. The company generates revenue through strategic partnerships and collaborations with various stakeholders, including research institutions and investment firms. These collaborations often involve co-development agreements and licensing arrangements for their innovative drugs, particularly YR-001 and other pipeline products. Although specific pricing structures for products and services have not been disclosed, the company’s revenue model is expected to involve B2B transactions, with potential collaborations leading to shared revenues from successful drug approvals and sales. Such partnerships are designed to maximize the reach and impact of Yirui Pharma’s therapeutic solutions in the global market.In December 2023, YIRUI Pharmaceutical Technology raised an undisclosed amount led by new investor Tailong VC, with participation from Tianlong Group and Hangzhou Win-Light Investment Co., Ltd. The company will utilize this funding to expedite the clinical trials of its YR-001 drug and to advance its projects. YIRUI plans to further develop new products targeting additional autoimmune conditions and expand its market presence, particularly in regions with high medical needs, leveraging the recent funds to support these initiatives.

## Funding rounds

- Series A, Dec 19, 2023 — Hangzhou Win-Light Investment Co., Ltd, Tianlong Group, Tailong VC

## Investors

- Hangzhou Win-Light Investment Co., Ltd — Series A
- Tianlong Group (https://capitalatlas.ai/funds/tianlong-group) — Series A
- Tailong VC (https://capitalatlas.ai/funds/tailong-vc) — Series A